SpiceJet records zero Level 1 safety findings in DGCA audits over the past year
SpiceJet on Tuesday announced that it recorded zero Level 1 safety findings in audits conducted by the Directorate General of Civil Aviation (DGCA) over the last one year. Level 1 findings represent the most serious category in aviation safety assessments, and the airline's performance has been hailed as a strong endorsement of its operational integrity.
In a statement, the airline said, 'We are happy to be recognised as India's safe airline.' The carrier emphasised that safety remains a top priority, and the DGCA's clean sheet result is a reflection of its strict adherence to regulatory norms and global aviation best practices.
The airline further highlighted that it successfully renewed its IATA Operational Safety Audit (IOSA) certification earlier this year in March. This certification, valid until March 2027, is a globally recognised benchmark for operational safety. The audit was conducted by the International Air Transport Association (IATA) and affirms SpiceJet's continued commitment to high safety and operational standards.
SpiceJet operates a fleet of Boeing 737s and Q-400 aircraft, and is one of the country's largest regional operators under the UDAN scheme. It also offers SpiceMax, a premium economy-class product, on most of its fleet.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
Terreno Realty Corporation Increases Quarterly Dividend by 6.1% and Files Second Quarter 2025 Financial Statements
BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation (NYSE: TRNO), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, declared a regular cash dividend for the quarter ending September 30, 2025 of $0.52 per common share, an increase of 6.1% over the prior dividend level. The dividend will be payable on October 10, 2025 to common stockholders of record at the close of business on September 29, 2025. Terreno Realty Corporation filed its quarterly report on Form 10-Q for the quarter ended June 30, 2025 with the U.S. Securities and Exchange Commission. The financial statements and supplemental financial information are available in the Investors & Media section of Terreno Realty Corporation's website, Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey, Los Angeles, Miami, San Francisco Bay Area, Seattle and Washington, D.C. Additional information about Terreno Realty Corporation is available on the company's web site at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. We caution investors that forward-looking statements are based on management's beliefs and on assumptions made by, and information currently available to, management. When used, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'project,' 'result,' 'should,' 'will,' 'seek,' 'target,' 'see,' 'likely,' 'position,' 'opportunity,' 'outlook,' 'potential,' 'enthusiastic,' 'future' and similar expressions which do not relate solely to historical matters are intended to identify forward-looking statements. These statements are subject to risks, uncertainties, and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control, including risks related to our ability to meet our estimated forecasts related to stabilized cap rates, and those risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other public filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, or projected. We expressly disclaim any responsibility to update our forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on results and trends at the time they are made, to anticipate future results or trends.
Business Wire
8 hours ago
- Business Wire
CRH plc (the "Company") Form 10-Q for the quarterly period ended June 30, 2025
NEW YORK--(BUSINESS WIRE)--A Form 10-Q for the quarterly period ended June 30, 2025 (the 'Form 10-Q') has been filed with the U.S. Securities and Exchange Commission (the "SEC") today. The Form 10-Q is available to view on the SEC's website at: and the Company's website at: https://
Business Wire
8 hours ago
- Business Wire
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. 'Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx,' said John Hanna, CEO of CareDx. 'His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase.' In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. 'On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO,' said John Hanna. 'Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best.' About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
